Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

PLoS Medicine

Volumn 10, Issue 9, 2013, Pages

  Feikin, Daniel R ^a,a,b   Kagucia, Eunice W ^a,a   Loo, Jennifer D ^b   Link Gelles, Ruth ^b   Puhan, Milo A ^a,a   Cherian, Thomas ^c,c   Levine, Orin S ^a   Whitney, Cynthia G ^b,am   O'Brien, Katherine L ^a,a   Moore, Matthew R ^b,am   Adegbola, Richard A ^d   Agocs, Mary ^c   Ampofo, Krow ^e   Andrews, Nick ^f   Barton, Theresa ^g   Benito, Javier ^h   Broome, Claire V ⁱ   Bruce, Michael G ^j   Bulkow, Lisa R ^j   Byington, Carrie L ^e   Camou, Teresa ^k   Cook, Heather ^l   Cotter, Suzanne ^m   Dagan, Ron ⁿ   de Wals, Philippe ^o   Deceuninck, Geneviève ^p   Denham, Barbara ^q   Edwards, Giles ^q   Eskola, Juhani ^r   Fitzgerald, Margaret ^m   Galanakis, Emmanouil ^s   Garcia Gabarrot, Gabriela ^k   Garcia Garcia, Juan J ^t   Gene, Amadeu ^t   Gomez, Borja ^h   Heffernan, Helen ^u   Hennessy, Thomas W ^j   Heuberger, Sigrid ^v   Hilty, Markus ^w   Ingels, Helene ^x   Jayasinghe, Sanjay ^y   Kellner, James D ^z   Klein, Nicola P ^aa   Kormann Klement, Andrea ^v   Kozakova, Jana ^ab   Krause, Vicki ^l   Kriz, Paula ^ab   Lambertsen, Lotte ^x   Lepoutre, Agnès ^ac   Lipsitch, Marc ^ad   Lopez Vega, Mariana ^k   Lovgren, Marguerite ^ae   Maraki, Sofia ^af   Mason, Edward O ^ag   McIntyre, Peter B ^ah   Menzies, Robert ^ah   Messina, Allison ^ai   Miller, Elizabeth ^f   Mintegi, Santiago ^h   Motlova, Jitka ^ab   Moulton, Lawrence H ^a   Mühlemann, Kathrin ^w   Muñoz Almagro, Carmen ^t   Murdoch, David R ^aj   Park, Daniel E ^a   Reingold, Arthur L ^ak   Sa Leao, Raquel ^al   Sanyal, Abanti ^a   Smith, Peter G ^am   Spanjaard, Lodewijk ^an   Techasaensiri, Chonnamet ^ao   Thompson, Richard E ^a   Thoon, Koh C ^ap   Tyrrell, Gregory J ^ae   Valentiner Branth, Palle ^x   van der Ende, Arie ^an   Vanderkooi, Otto G ^z   van der Linden, Mark P G ^aq   Varon, Emmanuelle ^ar   Verhaegen, Jan ^as   Vestrheim, Didrik F ^at   Vickers, Imelda ^au   von Gottberg, Anne ^av   von Kries, Rüdiger ^aw   Waight, Pauline ^f   Weatherholtz, Robert ^a   Weiss, Susanne ^aw   Yee, Arnold ^aa   Zaidi, Anita K M ^ax   more..

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^e UNIVERSITY OF UTAH   (United States)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h HOSPITAL DE CRUCES   (Spain)

ⁱ EMORY UNIVERSITY   (United States)

^j NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^k Departamento de Laboratorios   (Uruguay)

^l Centre for Disease Control   (Australia)

^m HEALTH PROTECTION SURVEILLANCE CENTRE   (Ireland)

ⁿ BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^o Institut National de Sante Publique   (Canada)

^p LAVAL UNIVERSITY   (Canada)

^q Meningococcus and Pneumococus Reference Laboratory   (United Kingdom)

^r NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^s UNIVERSITY OF CRETE   (Greece)

^t HOSPITAL SANT JOAN DE DÉU   (Spain)

^u INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^v AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY   (Austria)

^w UNIVERSITY OF BERN   (Switzerland)

^x STATENS SERUM INSTITUT   (Denmark)

^y UNIVERSITY OF SYDNEY   (Australia)

^z UNIVERSITY OF CALGARY   (Canada)

^aa KAISER PERMANENTE   (United States)

^ab NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^ac French Institute for Public Health Surveillance   (France)

^ad HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^ae PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

^af UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^ag BAYLOR COLLEGE OF MEDICINE   (United States)

^ah CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^ai JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^aj UNIVERSITY OF OTAGO   (New Zealand)

^ak UNIVERSITY OF CALIFORNIA   (United States)

^al UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^am LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^an ACADEMIC MEDICAL CENTER   (Netherlands)

^ao MAHIDOL UNIVERSITY   (Thailand)

^ap NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^aq UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^ar HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^as UNIVERSITY OF LEUVEN   (Belgium)

^at NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^au ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^av NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^aw UNIVERSITY OF MUNICH   (Germany)

^ax AGA KHAN UNIVERSITY   (Pakistan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHECKLIST; CHILD; DISEASE SURVEILLANCE; GEOGRAPHIC DISTRIBUTION; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INCIDENCE; INCOME; MAJOR CLINICAL STUDY; MENINGITIS; META ANALYSIS; PNEUMOCOCCAL INFECTION; PREVALENCE; SEROTYPE; VACCINATION;

ADOLESCENT; ADULT; AGED; CHILD, PRESCHOOL; DATABASES AS TOPIC; HEALTH PLANNING GUIDELINES; HUMANS; MENINGITIS, PNEUMOCOCCAL; META-ANALYSIS AS TOPIC; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; SEROTYPING; YOUNG ADULT;

EID: 84884637235     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001517     Document Type: Article

References (60)

1. World Health Organization (2012) Estimated Hib and pneumococcal deaths for children under 5 years of age, 2008. Available: http://www.who.int/immunization_monitoring/burden/Pneumo_hib_estimates/en/index.html. Accessed 18 February 2013.
2. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, et al. (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201: 32-41.
3. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, et al. (2009) Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 49: 205-212.
4. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, et al. (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297: 1784-1792.
5. O'Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R, et al. (2007) Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 196: 1211-1220.
6. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, et al. (2005) Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116: e408-e413.
7. Flasche S, Van Hoek AJ, Sheasby E, Waight P, Andrews N, et al. (2011) Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 8: e1001017 doi:10.1371/journal.pmed.1001017.
8. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374: 893-902.
9. Abdullahi O, Karani A, Tigoi CC, Mugo D, Kungu S, et al. (2012) The prevalence and risk factors for pneumococcal colonization of the nasopharynx among children in Kilifi District, Kenya. PLoS One 7: e30787 doi:10.1371/journal.pone.0030787.
10. World Health Organization (2010) Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol Rec 85: 434-436.
11. Conklin L, Knoll MD, Loo JD, Fleming-Dutra K, Park D, et al. (2011) Landscape analysis of pneumococcal conjugate vaccine dosing schedules: A systematic review (Report to the Strategic Advisory Group of Experts on Immunization (SAGE), World Health Organization). Available: http://www.who.int/immunization/sage/3_Conklin_L_PCV_Dosing_Landscape_Report_Oct_17_2011_FINAL_nov11.pdf. Accessed 18 February 2013.
12. Park IH, Moore MR, Treanor JJ, Pelton SI, Pilishvili T, et al. (2008) Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 198: 1818-1822.
13. Hausdorff WP, Siber G, Paradiso PR, (2001) Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 357: 950-952.
14. Weinberger DM, Malley R, Lipsitch M, (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 378: 1962-1973.
15. Hanquet G, Lernout T, Vergison A, Verhaegen J, Kissling E, et al. (2011) Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine 29: 2856-2864.
16. Miller E, Andrews NJ, Waight PA, Slack MP, George RC, (2011) Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 11: 760-768.
17. Cox C, (1990) Fieller's Theorem, the Likelihood and the Delta Method. Biometrics 46: 709-718.
18. Beaton GH, United Nations. Subcommittee on Nutrition (1992) Effectiveness of vitamin A supplementation in the control of young child morbidity and mortality in developing countries. Nutrition policy discussion paper number 13. Geneva: ACC/SCN. 120p.
19. Sweeting MJ, Sutton AJ, Lambert PC, (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23: 1351-1375.
20. Borenstein M, Hedges L., Rothstein H. (2007) Introduction to meta-analysis. pp.2-303. Available: http://www.meta-analysis.com/downloads/Meta%20Analysis%20Fixed%20vs%20Random%20effects.pdf. Accessed 18 February 2013.
21. Krause VL, Reid SJ, Merianos A, (2000) Invasive pneumococcal disease in the Northern Territory of Australia, 1994-1998. Med J Aust 173 Suppl: S27-31.
22. Barry C, Krause VL, Cook HM, Menzies RI, (2012) Invasive pneumococcal disease in Australia 2007 and 2008. Commun Dis Intell Q Rep 36: E151-165.
23. Motlova J, Benes C, Kriz P, (2009) Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997-2006. Epidemiol Infect 137: 562-569.
24. Harboe ZB, Valentiner-Branth P, Ingels H, Rasmussen JN, Andersen PH, et al. (2013) Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark. PLoS ONE 8: e51460 doi:10.1371/journal.pone.0051460.
25. Grall N, Hurmic O, Al Nakib M, Longo M, Poyart C, et al. (2011) Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine. Eur J Clin Microbiol Infect Dis 30: 1511-1519.
26. Zissis NP, Syriopoulou V, Kafetzis D, Daikos GL, Tsilimingaki A, et al. (2004) Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive infections and acute otitis media in children. Eur J Pediatr 163: 364-368.
27. Vickers I, Fitzgerald M, Murchan S, Cotter S, O'FlanaganO'Flanagan D, et al. (2011) Serotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland. Epidemiol Infect 139: 783-790.
28. Ben-Shimol S, Greenberg D, Givon-Lavi N, Elias N, Glikman D, et al. (2012) Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. Vaccine 30: 6600-6607.
29. van Deursen AM, van Mens SP, Sanders EA, Vlaminckx BJ, de Melker HE, et al. (2012) Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis 18: 1729-1737.
30. Heffernan HM, Martin DR, Woodhouse RE, Morgan J, Blackmore TK, (2008) Invasive pneumococcal disease in New Zealand 1998-2005: capsular serotypes and antimicrobial resistance. Epidemiol Infect 136: 352-359.
31. Vestrheim DF, Lovoll O, Aaberge IS, Caugant DA, Hoiby EA, et al. (2008) Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26: 3277-3281.
32. Lamb KE, Flasche S, Diggle M, Inverarity D, Greenhalgh D, et al. (2013) Trends in serotypes and sequence types among cases of invasive pneumococcal disease in Scotland, 1999-2010. Vaccine. In press.
33. Pilishvili T, Zell ER, Farley MM, Schaffner W, Lynfield R, et al. (2010) Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. Pediatrics 126: e9-e17.
34. Weatherholtz R, Millar EV, Moulton LH, Reid R, Rudolph K, et al. (2010) Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis 50: 1238-1246.
35. Black S, France EK, Isaacman D, Bracken L, Lewis E, et al. (2007) Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 26: 771-777.
36. Byington CL, Samore MH, Stoddard GJ, Barlow S, Daly J, et al. (2005) Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 41: 21-29.
37. GAVI Alliance (2011) GAVI Alliance Country Eligibility Policy. Available: www.gavialliance.org/about/governance/programme-policies/country-eligibility/. Accessed 31 May 2013.
38. Black S, (2010) The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation. Pediatr Infect Dis J 29: 301-303.
39. World Health Organization (2012) Pneumococcal vaccine WHO position paper- 2012. Wkly Epidemiol Rec 14: 129-144.
40. Miller E, Andrews NJ, Waight PA, Slack MP, George RC, (2011) Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 29: 9127-9131.
41. Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, et al. (2012) Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 381: 214-222.
42. Singleton R, Wenger J, Klejka JA, Bulkow LR, Thompson A, et al. (2013) The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska Native children: results of a clinical trial. Pediatr Infect Dis J 32: 257-263.
43. Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, et al. (2004) Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 190: 1203-1211.
44. Bogaert D, Thompson CM, Trzcinski K, Malley R, Lipsitch M, (2010) The role of complement in innate and adaptive immunity to pneumococcal colonization and sepsis in a murine model. Vaccine 28: 681-685.
45. Sleeman KL, Griffiths D, Shackley F, Diggle L, Gupta S, et al. (2006) Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis 194: 682-688.
46. Weinberger DM, Harboe ZB, Flasche S, Scott JA, Lipsitch M, (2011) Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations. Epidemiology 22: 199-207.
47. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348: 1737-1746.
48. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, et al. (2009) Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 360: 244-256.
49. Cohen AL, Harrison LH, Farley MM, Reingold AL, Hadler J, et al. (2010) Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 24: 2253-2262.
50. Feikin DR, Klugman KP, (2002) Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 35: 547-555.
51. Fenoll A, Martin Bourgon C, Munoz R, Vicioso D, Casal J, (1991) Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis 13: 56-60.
52. Harboe ZB, Benfield TL, Valentiner-Branth P, Hjuler T, Lambertsen L, et al. (2010) Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 50: 329-337.
53. Lagos R, Munoz A, San Martin O, Maldonado A, Hormazabal JC, et al. (2008) Age- and serotype-specific pediatric invasive pneumococcal disease: insights from systematic surveillance in Santiago, Chile, 1994-2007. J Infect Dis 198: 1809-1817.
54. Hausdorff WP, Feikin DR, Klugman KP, (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5: 83-93.
55. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N, (2009) Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 199: 776-785.
56. Hausdorff WP, Van Dyke MK, Van Effelterre T (2012) Serotype replacement after pneumococcal vaccination. Lancet 379: 1387-1388; author reply 1388-1389.
57. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, et al. (2010) Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375: 1969-1987.
58. World Health Organization (2012) Review of serotype replacement in the setting of 7-valent pneumococcal conjugate vaccine (PCV-7) use and implications for the PCV10/PCV13 era. Wkly Epidemiol Rec 87: 12-13.
59. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, et al. (2001) Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 285: 1729-1735.
60. van Deursen AM, van Mens SP, Sanders EA, Vlaminckx BJ, de Melker HE, et al. (2012) Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis 18: 1729-1737.